Matthew Maurer

Has grant

Assistant Professor of Biostatistics and Medicine

Mayo Clinic Rochester

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Matthew Maurer is an Assistant Professor of Biostatistics and Medicine at the Mayo Clinic Rochester, USA. His research focuses on oncology, particularly in the areas of lymphoma, predictive modeling in cancer, and the implications of cancer screening. He has authored several significant articles, including those on the prediction models in advanced Hodgkin lymphoma and the characteristics of diffuse large B-cell lymphoma.

Recent Grants

Grant: Close

Defining clinical risk and treatment preferences for patients living with follicular lymphoma

Open Date: 2023-03-01

Close Date: 2026-02-28

Articles (27)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (21)

Umar Farooq

Assistant Professor

University of Iowa Healthcare

UNITED STATES

Matthew Maurer

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (27)

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

Characteristics and outcomes of incidentally diagnosed diffuse large B‐cell lymphoma and implications for cancer screening

Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models

The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line

Defining primary refractory large B-cell lymphoma

What clinicians should know about surrogate end points in hematologic malignancies

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot

Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature

Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy.

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis

Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts

Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes

Collaborators (21)

Umar Farooq

James Cerhan

Judit Meszaros Joergensen

Januario E. Castro, M.D.

Chan Yoon Cheah

Andrea Gallamini

Richard Burack

Amer Beitinjaneh

Emanuele Zucca

Laurie H. Sehn

Eric Mou

Miriam Jacobs

Michael Buege

Dai Chihara

Eliza Hawkes

Katharine Lewis

David Bond

Lisa Rimsza

Christopher Strouse

Sergei Syrbu

david jaye

Make your next move.